Vertex Appoints Charles Wagner as Chief Financial Officer
April 02 2019 - 8:00AM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced the appointment of Charles (Charlie) Wagner as Executive
Vice President and Chief Financial Officer (CFO), effective April
10, 2019. Mr. Wagner will report directly to Vertex Chairman,
President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D.,
and oversee the finance, internal audit, investor relations, and
global security and facilities functions. Mr. Wagner joins Vertex
with deep corporate finance and health care experience, including
more than a decade in public and private company CFO roles.
“Charlie is a proven finance leader with extensive experience
working in a public company setting, and he will be a tremendous
asset to Vertex and our strong team,” said Dr. Leiden. “As we
continue to build Vertex for the future, Charlie’s strategic
mindset, operational expertise, and broad leadership experience
will prove invaluable. I’d like to thank our interim CFO, Paul
Silva, for his contributions and leadership. Paul will continue in
his role as Corporate Controller upon Charlie’s arrival.”
Mr. Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. –
a Carlyle Group portfolio company, where he served as CFO and EVP,
Finance. In this role, he had leadership responsibilities for all
aspects of finance, accounting, tax, treasury, global information
systems, lender relations, and acquisitions and divestitures, as
well as shared responsibility for several enterprise-wide projects.
Prior to this, Mr. Wagner served as CFO for publicly- traded Bruker
Corporation, Progress Software Corporation and Millipore
Corporation. In addition to his corporate finance roles, Mr. Wagner
served as an advisor at Bain & Company and Coopers &
Lybrand. He received his BS in accounting from Boston College and
his MBA from Harvard Business School.
“I am excited to be joining Vertex at such a dynamic time as the
company continues to deliver more transformational medicines for
cystic fibrosis patients and accelerates its pipeline of innovative
and novel life-changing treatments for patients with other serious
diseases,” said Mr. Wagner. “I look forward to working with
Vertex’s senior leadership team and employees to help the company
continue to drive value through its remarkable innovation.”
About Vertex
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious and life-threatening diseases. In addition to clinical
development programs in CF, Vertex has more than a dozen ongoing
research programs focused on the underlying mechanisms of other
serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is
now located in Boston's Innovation District. Today, the company has
research and development sites and commercial offices in the United
States, Europe, Canada, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including being named to Science magazine's Top Employers in
the life sciences ranking for nine years in a row.
For additional information and the latest updates from the
company, please visit www.vrtx.com.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995,
including, without limitation, the statements in the second and
fourth paragraphs of this press release. While Vertex believes the
forward-looking statements contained in this press release are
accurate, there are a number of factors that could cause actual
events or results to differ materially from those indicated by such
forward-looking statements. Those risks and uncertainties include,
among other things, risks listed under Risk Factors in Vertex's
annual report and quarterly reports filed with the Securities and
Exchange Commission. Vertex disclaims any obligation to update the
information contained in this press release as new information
becomes available.
(VRTX-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190402005193/en/
Vertex Pharmaceuticals
IncorporatedInvestors:Michael Partridge,
617-341-6108orEric Rojas, 617-961-7205orZach Barber,
617-341-6470
Media:617-341-6992mediainfo@vrtx.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024